MA39100B1 - Compositions and methods for reducing major adverse cardiovascular events - Google Patents
Compositions and methods for reducing major adverse cardiovascular eventsInfo
- Publication number
- MA39100B1 MA39100B1 MA39100A MA39100A MA39100B1 MA 39100 B1 MA39100 B1 MA 39100B1 MA 39100 A MA39100 A MA 39100A MA 39100 A MA39100 A MA 39100A MA 39100 B1 MA39100 B1 MA 39100B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- adverse cardiovascular
- compositions
- mace
- major adverse
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des compositions, des kits, des utilisations, des systèmes et des procédés pour utiliser de la naltrexone et du bupropion, ou des sels pharmaceutiquement acceptables de ces derniers, pour réduire le risque de conséquences ou d'événements cardiovasculaires indésirables, y compris des événements cardiovasculaires indésirables majeurs (mace) chez des sujets, de préférence ceux ayant un risque accru de conséquences cardiovasculaires indésirables ou mace, qui peuvent être en surpoids ou obèses. La présente invention concerne également des compositions, des kits, des utilisations, des systèmes et des procédés pour utiliser de la naltrexone et du bupropion, ou des sels pharmaceutiquement acceptables de ces derniers, pour le traitement du surpoids ou de l'obésité chez des sujets, de préférence ayant un risque accru de conséquences cardiovasculaires indésirables ou mace, le traitement réduisant le risque de mace.The present invention provides compositions, kits, uses, systems, and methods for using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, to reduce the risk of adverse cardiovascular consequences or events, including including major adverse cardiovascular events (mace) in subjects, preferably those at increased risk of adverse cardiovascular consequences or mace, who may be overweight or obese. The present invention also relates to compositions, kits, uses, systems and methods for using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for the treatment of overweight or obesity in subjects. , preferably having an increased risk of unwanted cardiovascular consequences or mace, the treatment reducing the risk of mace.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 | |
| US201361914935P | 2013-12-11 | 2013-12-11 | |
| US201461984580P | 2014-04-25 | 2014-04-25 | |
| US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
| PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39100A1 MA39100A1 (en) | 2018-01-31 |
| MA39100B1 true MA39100B1 (en) | 2019-12-31 |
Family
ID=61759232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39100A MA39100B1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA39100B1 (en) |
-
2014
- 2014-12-04 MA MA39100A patent/MA39100B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA39100A1 (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690964A1 (en) | COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR PHENOMENA | |
| SA519402217B1 (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| EP4026835A3 (en) | Pd-1/pd-l1 inhibitors | |
| WO2010094009A3 (en) | Methods and compositions for the treatment of ras associated disorders | |
| MA39211A1 (en) | Tricyclic compounds as anti-cancer agents | |
| UA109650C2 (en) | BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS | |
| MX2008016453A (en) | Compositions and methods for treating parasitic infections. | |
| EA201291309A1 (en) | USING SGC STIMULATORS, SGC ACTIVATORS, ONE AND IN COMBINATION WITH PDE5 INHIBITORS, TO TREAT SYSTEMIC SCLEROSIS | |
| BR112015020466A2 (en) | cdc7 inhibitors | |
| MA37714A1 (en) | Methods of treating overweight and obesity | |
| DOP2013000007A (en) | PYRIMIDINATED AND CONDENSED TRIAZINS AND THEIR USE | |
| EA201270567A1 (en) | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| WO2011035205A3 (en) | Antibodies against candida, collections thereof and methods of use | |
| RS53467B (en) | Use of amisulpride for treating chemotherapy-induced nausea and vomiting | |
| MA38827A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in the treatment of hyperproliferative diseases | |
| EA201591379A1 (en) | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA) INHIBITORS BASED ON 2,3-DIHYDROIMIDAZO [1,2-С] PYRIMIDIN-5 (1H) -OH | |
| RU2009120992A (en) | 3-ANDROSTANEDIOL USE, OPTIONAL IN COMBINATION WITH A 5-HT1A AGONIST FOR TREATMENT OF SEXUAL DYSFUNCTION | |
| BR112012029919A2 (en) | process for the preparation of 5-substituted 8-alkoxy [1,2,4] triazolo [1,5-c] pyrimidin-2-amines | |
| MA33839B1 (en) | Combinations and methods of diagnosis and treatment of tumors | |
| EA201390217A1 (en) | METHODS FOR THE TREATMENT OF ALCOHOL INTOXICATION, DISORDERS RELATED TO THE USE OF ALCOHOL, AND ABUSE OF ALCOHOL, THAT INCLUDE THE INTRODUCTION OF DIHYDROMYRICETIN | |
| WO2008063676A3 (en) | Treatment of injury to the brain by inhibition of acid sensing ion channels | |
| WO2012021800A3 (en) | Caspase inhibitors as therapeutics for neural and organ injury and imaging | |
| EA201500913A1 (en) | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| WO2015126930A3 (en) | Booster drug therapy for mycobacterium infections | |
| MX2009004142A (en) | Method of preventing or treating metabolic syndrome. |